Nicotinamide Adenine Dinucleotide Treatment Confers Resistance to Neonatal Ischemia and Hypoxia: Effects on Neurobehavioral Phenotypes

Overview

Journal Neural Regen Res

Date 2024 Apr 10

PMID 38595293

Authors

Xiaowen Xu

Xinxin Wang

Li Zhang

Yiming Jin

Lili Li

Meifang Jin

Lianyong Li

Hong Ni

Affiliations

Soon will be listed here.

Abstract

JOURNAL/nrgr/04.03/01300535-202412000-00031/figure1/v/2024-04-08T165401Z/r/image-tiff Neonatal hypoxic-ischemic brain injury is the main cause of hypoxic-ischemic encephalopathy and cerebral palsy. Currently, there are few effective clinical treatments for neonatal hypoxic-ischemic brain injury. Here, we investigated the neuroprotective and molecular mechanisms of exogenous nicotinamide adenine dinucleotide, which can protect against hypoxic injury in adulthood, in a mouse model of neonatal hypoxic-ischemic brain injury. In this study, nicotinamide adenine dinucleotide (5 mg/kg) was intraperitoneally administered 30 minutes before surgery and every 24 hours thereafter. The results showed that nicotinamide adenine dinucleotide treatment improved body weight, brain structure, adenosine triphosphate levels, oxidative damage, neurobehavioral test outcomes, and seizure threshold in experimental mice. Tandem mass tag proteomics revealed that numerous proteins were altered after nicotinamide adenine dinucleotide treatment in hypoxic-ischemic brain injury mice. Parallel reaction monitoring and western blotting confirmed changes in the expression levels of proteins including serine (or cysteine) peptidase inhibitor, clade A, member 3N, fibronectin 1, 5'-nucleotidase, cytosolic IA, microtubule associated protein 2, and complexin 2. Proteomics analyses showed that nicotinamide adenine dinucleotide ameliorated hypoxic-ischemic injury through inflammation-related signaling pathways (e.g., nuclear factor-kappa B, mitogen-activated protein kinase, and phosphatidylinositol 3 kinase/protein kinase B). These findings suggest that nicotinamide adenine dinucleotide treatment can improve neurobehavioral phenotypes in hypoxic-ischemic brain injury mice through inflammation-related pathways.

References

Lee H, Song J, Kim J, Jin S, Hong M, Park J . Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia. Behav Brain Funct. 2005; 1:15. PMC: 1215472. DOI: 10.1186/1744-9081-1-15. View

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

Pencina K, Valderrabano R, Wipper B, Orkaby A, Reid K, Storer T . Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. J Clin Endocrinol Metab. 2023; 108(8):1968-1980. PMC: 11491622. DOI: 10.1210/clinem/dgad027. View

Hou Y, Wei Y, Lautrup S, Yang B, Wang Y, Cordonnier S . NAD supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING. Proc Natl Acad Sci U S A. 2021; 118(37). PMC: 8449423. DOI: 10.1073/pnas.2011226118. View

Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau D, Zavala E . NAD supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc Natl Acad Sci U S A. 2018; 115(8):E1876-E1885. PMC: 5828618. DOI: 10.1073/pnas.1718819115. View

Klaidman L, Morales M, Kem S, Yang J, Chang M, Adams Jr J . Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function. Pharmacology. 2003; 69(3):150-7. DOI: 10.1159/000072668. View

Son M, Ryu J, Kim J, Kwon Y, Chung K, Mun S . Upregulation of mitochondrial NAD levels impairs the clonogenicity of SSEA1 glioblastoma tumor-initiating cells. Exp Mol Med. 2017; 49(6):e344. PMC: 5519015. DOI: 10.1038/emm.2017.74. View

Nakamura K, Osaka H, Murakami Y, Anzai R, Nishiyama K, Kodera H . PIGO mutations in intractable epilepsy and severe developmental delay with mild elevation of alkaline phosphatase levels. Epilepsia. 2014; 55(2):e13-7. DOI: 10.1111/epi.12508. View

Winerdal M, Winerdal M, Wang Y, Fredholm B, Winqvist O, Aden U . Adenosine A1 receptors contribute to immune regulation after neonatal hypoxic ischemic brain injury. Purinergic Signal. 2015; 12(1):89-101. PMC: 4749537. DOI: 10.1007/s11302-015-9482-3. View

10.

Savitz J . The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2019; 25(1):131-147. PMC: 6790159. DOI: 10.1038/s41380-019-0414-4. View

11.

Ji C, Tang Y, Zhang Y, Li C, Liang H, Ding L . Microglial glutaminase 1 deficiency mitigates neuroinflammation associated depression. Brain Behav Immun. 2021; 99:231-245. DOI: 10.1016/j.bbi.2021.10.009. View

12.

Chen N, Zhao D, Sun Y, Wang D, Ni H . Long-Term Effects of Zinc Deficiency and Zinc Supplementation on Developmental Seizure-Induced Brain Damage and the Underlying GPR39/ZnT-3 and MBP Expression in the Hippocampus. Front Neurosci. 2019; 13:920. PMC: 6737275. DOI: 10.3389/fnins.2019.00920. View

13.

Tan L, Jiang X, Xu L, Li G, Feng C, Ding X . TP53-induced glycolysis and apoptosis regulator alleviates hypoxia/ischemia-induced microglial pyroptosis and ischemic brain damage. Neural Regen Res. 2020; 16(6):1037-1043. PMC: 8224121. DOI: 10.4103/1673-5374.300453. View

14.

Kelley K, Pasca S . Human brain organogenesis: Toward a cellular understanding of development and disease. Cell. 2021; 185(1):42-61. DOI: 10.1016/j.cell.2021.10.003. View

15.

Zhou Y, Song W, Andhey P, Swain A, Levy T, Miller K . Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020; 26(1):131-142. PMC: 6980793. DOI: 10.1038/s41591-019-0695-9. View

16.

Vasquez-Vivar J, Shi Z, Jeong J, Luo K, Sharma A, Thirugnanam K . Neuronal vulnerability to fetal hypoxia-reoxygenation injury and motor deficit development relies on regional brain tetrahydrobiopterin levels. Redox Biol. 2020; 29:101407. PMC: 6928344. DOI: 10.1016/j.redox.2019.101407. View

17.

Nie L, He K, Xie F, Xiao S, Li S, Xu J . Loganin substantially ameliorates molecular deficits, pathologies and cognitive impairment in a mouse model of Alzheimer's disease. Aging (Albany NY). 2021; 13(20):23739-23756. PMC: 8580356. DOI: 10.18632/aging.203646. View

18.

Zeng X, Zhang Y, Ma R, Chen Y, Xiang X, Hou D . Activated Drp1 regulates p62-mediated autophagic flux and aggravates inflammation in cerebral ischemia-reperfusion via the ROS-RIP1/RIP3-exosome axis. Mil Med Res. 2022; 9(1):25. PMC: 9137164. DOI: 10.1186/s40779-022-00383-2. View

19.

Wei J, Wen W, Dai Y, Qin L, Wen Y, Duan D . Drinking water temperature affects cognitive function and progression of Alzheimer's disease in a mouse model. Acta Pharmacol Sin. 2020; 42(1):45-54. PMC: 7921420. DOI: 10.1038/s41401-020-0407-5. View

20.

Yu H, Sun T, Wang Z, Li H, Xu D, An J . Exendin-4 and linagliptin attenuate neuroinflammation in a mouse model of Parkinson's disease. Neural Regen Res. 2023; 18(8):1818-1826. PMC: 10154509. DOI: 10.4103/1673-5374.360242. View